Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

NCT01605825 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT01605825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01605825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Lead sponsor
Acorda Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
March 31, 2013
Enrollment
83 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke